Bicycle Therapeutics (BCYC) Net Margin (2018 - 2026)
Bicycle Therapeutics (BCYC) reported Net Margin of 6857.38% for Q1 2026, down 624844.0% on a YoY basis from N/an in Q1 2025, and down 16216.66% quarter-over-quarter from 42.03% in Q4 2025.
Bicycle Therapeutics (BCYC) Net Margin (2018 - 2026) Analysis & Trends
Bicycle Therapeutics has reported Net Margin for 9 years, with the latest figure at 6857.38% in Q1 2026.
- For the quarter ending Q1 2026, Net Margin fell 624844.0% year-over-year to 6857.38%; the trailing twelve-month figure through Mar 2026 stood at 344.95% (up 44512.0% YoY), and the FY2025 full-year result was 301.66%, up 17752.0% from the prior year.
- Net Margin for Q1 2026 stood at 6857.38%, down from 42.03% in the prior quarter.
- The five-year high for Net Margin was 42.03% in Q4 2025, with the low at 6857.38% in Q1 2026.
- Historically, Net Margin has averaged 1178.9% across 5 years, with a median of 714.09% in 2022.
- Annual changes were most pronounced in 2025 — Net Margin surged 139477 bps — and 2026, when it slumped 624844 bps.
- Bicycle Therapeutics' Net Margin stood at 356.88% in 2022, then tumbled by 158 bps to 921.01% in 2023, then slumped by 52 bps to 1398.44% in 2024, then surged by 97 bps to 42.03% in 2025, then tumbled by 16217 bps to 6857.38% in 2026.
- The last three Net Margin figures came in at 6857.38% (Q1 2026), 42.03% (Q4 2025), and 503.66% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.82% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 34.53% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Bicycle Therapeutics | 278.04 Mn | 278.04 Mn | - | -6,857.38% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6,857.38% |
| Dec 31, 2025 | -42.03% |
| Sep 30, 2025 | -503.66% |
| Jun 30, 2025 | -2,703.84% |
| Mar 31, 2025 | -608.94% |
| Dec 31, 2024 | -1,398.44% |
| Sep 30, 2024 | -1,898.43% |
| Jun 30, 2024 | -425.30% |
| Mar 31, 2024 | -255.41% |
| Dec 31, 2023 | -921.01% |
| Sep 30, 2023 | -932.32% |
| Jun 30, 2023 | -373.81% |
| Mar 31, 2023 | -797.88% |
| Dec 31, 2022 | -356.88% |
| Sep 30, 2022 | -932.47% |
| Jun 30, 2022 | -319.38% |
| Mar 31, 2022 | -714.09% |
| Dec 31, 2021 | -1,127.31% |
| Sep 30, 2021 | -338.75% |
| Jun 30, 2021 | -1,003.53% |